Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446

Article  CAS  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128

Article  CAS  PubMed  Google Scholar 

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657

Article  CAS  PubMed  Google Scholar 

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357

Article  CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306

Article  CAS  PubMed  Google Scholar 

Yau K, Dharia A, Alrowiyti I, Cherney DZI (2022) Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep 7(7):1463–1476

Article  PubMed  PubMed Central  Google Scholar 

Patel N, Hindi J, Farouk SS (2021) Sodium-glucose cotransporter 2 inhibitors and kidney transplantation: what are we waiting for? Kidney 2(7):1174–1178

Article  Google Scholar 

Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W et al (2018) Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6(9):691–704

Article  CAS  PubMed  Google Scholar 

Long B, Lentz S, Koyfman A, Gottlieb M (2021) Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med 44:157–160

Article  PubMed  Google Scholar 

KDIGO Announces Launch of CKD Guideline Update – KDIGO [Internet]. [cited 2023 Mar 21]. Available from: https://kdigo.org/kdigo-announces-launch-of-ckd-guidelineupdate/

Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF et al (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dial Transplant 37(9):1647–1656

Article  CAS  PubMed  Google Scholar 

Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T et al (2021) A prespecified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215–224

Article  CAS  PubMed  Google Scholar 

EMPA-KIDNEY Collaborative Group (2022) Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 37(7):1317–1329

Article  Google Scholar 

Empagliflozin in patients with chronic kidney disease (2023) N Engl J Med 388(2):117–127

Article  Google Scholar 

Rajasekeran H, Kim SJ, Cardella CJ, Schiff J, Cattral M, Cherney DZI et al (2017) Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series. Diabetes Care 40(7):e75–e76

Article  PubMed  Google Scholar 

Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J et al (2019) Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 42(6):1067–1074

Article  CAS  PubMed  Google Scholar 

Schwaiger E, Burghart L, Signorini L, Ristl R, Kopecky C, Tura A et al (2019) Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 19(3):907–919

Article  CAS  PubMed  PubMed Central  Google Scholar 

Attallah N, Yassine L (2019) Use of empagliflozin in recipients of kidney transplant: a report of 8 cases. Transplant Proc 51(10):3275–3280

Article  CAS  PubMed  Google Scholar 

Mahling M, Schork A, Nadalin S, Fritsche A, Heyne N, Guthoff M (2019) Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 44(5):984–992

Article  CAS  PubMed  Google Scholar 

Lim J-H, Kwon S, Jeon Y, Kim YH, Kwon H, Kim YS et al (2022) The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation 106(9):e404–e412

Article  CAS  PubMed  Google Scholar 

Hammad H, Shaaban A, Philips MV, Fayed A, Abdelaziz TS (2023) Effect of sodium-glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial. Int Urol Nephrol. https://doi.org/10.1007/s11255-023-03539-8

Article  PubMed  Google Scholar